Governance Documents

The Board of Directors of GI Dynamics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Management Team


Scott Schorer, President and Chief Executive Officer

Mr. Schorer has served as a consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He was Chief Executive Officer of PlasmaTech Biopharmaceuticals, Inc. from September 2014 to June 2015. From May 2010 to September 2014, Schorer ran an interim leadership and strategic consulting practice under the name of SSMC. From February 2009 to May 2010, Schorer led the turnaround effort at Systagenix Wound Management, the former Advanced Wound Care division of Johnson & Johnson, as President of the Americas. Prior to that, Schorer founded and led IST: Innovative Spinal Technologies, where he served as CEO for eight years until February 2009, during which time IST received CE Mark and FDA approvals for five products before the company was sold to Integra Spine. Prior to IST, he co-founded and was CEO of CentriMed, leading to an acquisition by Global Healthcare Exchange (“GHX”). Schorer began his medical device career as a sales representative for a surgical distributor following his career as an infantry officer in the 82nd Airborne Division as a rifle and scout platoon leader. He has led financing for over $120 million in public and private equity financings. Schorer is also a co-inventor of 6 patents, and holds Bachelor of Arts and Bachelor of Engineering degrees from Dartmouth College, where he was also captain of the men’s crew.


Brian Callahan, Chief Compliance Officer, Executive Vice President of Clinical, Regulatory, and Quality Affairs

Mr. Callahan is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries. He began his career in the United States Army as a nuclear weapons specialist and has experience working for Johnson & Johnson, Covidien and Quintiles. In 2002, Callahan founded EEC & Associates, a global compliance consulting company providing clinical, regulatory and quality services to domestic and international life science companies. More recently, Callahan was Executive Vice President of Clinical, Quality and Regulatory Affairs at Histogenics Corporation and was instrumental in raising $49 million to restart the NeoCart Pivotal Phase III study.


Houry Youssoufian, Vice President of Finance and Accounting

Ms. Youssoufian is an accomplished senior finance executive with more than 20 years of experience in publicly and privately traded, high-growth and transition stage companies mainly focused in the life science sector. She has her MBA from Simmons College Graduate School of Management and earned her CPA while working at Price Waterhouse Coopers.

Prior to joining GI Dynamics, Youssoufian served as a consultant to various biotechnology companies including Sage Therapeutics, Voyager Therapeutics and Infinity Pharmaceutical. She has been Vice President of Finance at Immunetics, Inc., and Site Head of Finance at Novartis Institute of Biomedical Research Inc.

Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.


Daniel J. Moore (Chairman)

In addition to serving as Chairman of the GI Dynamics board, Mr. Moore is also the President and CEO of the Cyberonics medical device company.


Dr. Oern Stuge

Dr. Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.


Timothy J. Barberich

In addition to GI Dynamics, Mr. Barberich also serves on the boards of Heartware International, Inc., Tokai Pharmaceuticals, Euthymics Neuroscience, and Newcastle Holdings. He is a chairman of BioNevia Pharmaceuticals, and is the founder and former CEO of Sepracor, Inc.


Juliet Thompson

Ms. Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dyanmics, Thompson also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.